The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 25, Issue 2, 2010, Pages 191-201

  Rockwood, Kenneth ^a   Fay, Sherri ^a   Gorman, Mary ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b St Martha's Regional Hospital   (Canada)

Author keywords

ADAS cog; Alzheimer's disease; Clinical meaningfulness; Judgement based measures; VISTA

Indexed keywords

GALANTAMINE; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GOAL ATTAINMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; SEVERITY OF ILLNESS INDEX;

EID: 75749127334     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2319     Document Type: Article

References (28)

1. Birks J. 2006. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Reviews, January 25, Issue (1), CD005593.
2. Burback D, Molnar FJ, St John P, Man-Song-Hing M. 1999. Key methodological features of randomized controlled trials of Alzheimer's disease therapy: minimal clinically important difference, sample size and trial duration. Dement Geriatr Cogn Disord 10: 534-540. DOI: 10.1159/000017201
3. Burns A. 2002. Meaningful treatment outcomes in Alzheimer's disease. J Neurol Neurosurg Psychiatry 73: 471-472.
4. Burns A, O'Brien J. BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D, British Association for Psychopharmacology. 2006. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 20: 732-755.
5. Burns A, Yeates A, Akintade L, del Valle M, Zhang RY, Schwam EM, Perdomo CA. 2008. Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies. Drugs Aging 25: 707-714.
6. Frank LB. 2007. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Report from the Alzheimer's Association Research Roundtable on patient-reported outcomes and dementia research. Alzheimers Dement 3: 162-165.
7. Gammanpila UP, Burns A, Heller RF, Purandare N. 2007. What are the benefits of cognitive enhancers for Alzheimer's disease: use of population impact measures. BMC Geriatr 7: 25. DOI: 10.1186/1471-2318-7-25
8. Helmer C, Andrieu S, Pérès K, Orgogozoa J-M, Vellasc B, Dartiguesa J-F. 2007. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease. Dement Geriatr Cogn Disord 23: 168-174. DOI: 10.1159/000098516
9. Hirsch C. 2006. Galantamine was effective in mild-to-moderate Alzheimer disease. ACP J Club 145: 50.
10. Joffres C, Bucks RS, Haworth J, Wilcock GK, Rockwood K. 2003. Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis. Demen Geriatric Cog Disord 15: 26-33. DOI: 10.1159/000066673
11. Joffres C, Graham JE, Rockwood K. 2000. Qualitative analysis of the alinician interview-based impression of change (plus): methodological issues and implications for clinical research. Int Psychogeriatr 12: 403-413. DOI: 10.1017/S1041610200006505
12. Kiresuk TJ, Sherman RE. 1968. Goal attainment scaling: a general method for evaluating comprehensive community health programs. Community Ment Health J 4: 443-453. DOI: 10.1007/BF01530764
13. Livingston G, Katona C. 2000. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry 15: 203-207.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stedlan EM. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
15. Qaseem A, Snow V, Cross JT, Firciea MA, Hopkins R, Shekelle P, Adelman A, Mehr D, Schellhase K, Campos-Outcalt D, Santaguida P, Owens DK. and the Joint American College of Physicians/American Academy of Family Physicians Panel on Dementia. 2008. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 148: 370-378.
16. Quinn J, Moore M, Benson DF, Clark CM, Doody R, Jagust W, Knopman D, Kaye JA. 2002. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology 58: 433-437.
17. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. 2008. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379-397.
18. Rockwood K. 2004. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 677-685. Erratum in: 2004. J Neurol Neurosurg Psychiatry 75: 1086.
19. Rockwood K, Fay S, Gorman M, Carver D, Graham JE. 2007a. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurology 7: 26. DOI: 10.1186/1471-2377-7-26
20. Rockwood K, Fay S, Jarrett P, Asp E. 2007b. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. Neurology 68: 1116-1121.
21. Rockwood K, Fay S, Song X, MacKnight C, Gorman M. 2006. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized control trial. CMAJ 174: 1099-1105. DOI: 10.1503/cmaj.051432
22. Rockwood K, Graham JE, Fay S. 2002. Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 73: 500-507.
23. Rockwood K, MacKnight C. 2001. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemioly 20: 51-56.
24. Rosen WG, Mohs RC, Davis KL. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364.
25. Schneider LS, Olin JT. 1996. Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr 8: 277-288.
26. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL. 1994. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151: 390-396.
27. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C. 2006. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 21: 17-28. DOI: 10.1002/gps.1402
28. Vellas B, Andrieu S, Cantet C, Dartigues JF, Gauthier S. 2007. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer? J Nutr Health Aging 11: 338-341.